Founded by a team of scientists, physicians, and engineers, Alveolus Bio is dedicated to pioneering breakthrough FDA-approved therapeutics for lung diseases. The company's core mission is to disrupt the standard of care for chronic and infectious lung diseases through innovative biotherapeutic delivery. Their proprietary resMIT platform targets fibroblast dysfunction in Idiopathic Pulmonary Fibrosis (IPF) and neutrophilic inflammation, with a clinical pipeline that includes preclinical phase live biotherapeutics for conditions like Bronchopulmonary Dysplasia (BPD) and Chronic Obstructive Pulmonary Disease (COPD).

Notable affiliated individuals include leading scientists and clinicians in the field of pulmonology. Alveolus Bio has garnered attention from key investors in the biotech sector, contributing to its rapid development and clinical advancements. The company has achieved significant milestones in preclinical trials, positioning itself as a transformative force in lung disease treatment. Through its innovative approach, Alveolus Bio aims to significantly improve patient outcomes and set new standards in the treatment of chronic lung conditions.